Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics for unmet medical needs.
Our key therapeutic target, Rho-associated coiled-coil kinase (ROCK), is an “on” switch in cells that regulates cell movement, shape and differentiation. We have a portfolio of small molecule ROCK inhibitors in preclinical and clinical development to treat autoimmune, fibrotic and neurodegenerative diseases. Our lead ROCK inhibitor candidate, KD025, is being studied in ongoing Phase 2 clinical trials in chronic graft-versus-host disease (cGVHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis.
In addition to our ROCK inhibitor compounds, we are developing monoclonal antibodies as well as fusion proteins and bi-specific antibodies that we believe will represent the next generation of cancer therapeutics.